Comparing Certara (NASDAQ:CERT) and Alpha Cognition (NASDAQ:ACOG)

Certara (NASDAQ:CERT) and Alpha Cognition (NASDAQ:ACOG) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, dividends, earnings and risk.

Analyst Ratings

This is a breakdown of current ratings and target prices for Certara and Alpha Cognition, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Certara	1	6	5	1	2.46
Alpha Cognition	0	0	2	0	3.00

Certara currently has a consensus price target of $10.44, indicating a potential upside of 74.07%. Alpha Cognition has a consensus price target of $16.00, indicating a potential upside of 133.58%. Given Alpha Cognition’s stronger consensus rating and higher possible upside, analysts clearly believe Alpha Cognition is more favorable than Certara.

Risk and Volatility

Certara has a beta of 1.62, suggesting that its share price is 62% more volatile than the S&P 500. Comparatively, Alpha Cognition has a beta of 2.51, suggesting that its share price is 151% more volatile than the S&P 500.

Insider and Institutional Ownership

74.0% of Certara shares are owned by institutional investors. 1.1% of Certara shares are owned by insiders. Comparatively, 14.0% of Alpha Cognition shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Certara and Alpha Cognition’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Certara	-0.38%	4.20%	2.90%
Alpha Cognition	-202.23%	-55.71%	-43.78%

Valuation & Earnings

This table compares Certara and Alpha Cognition”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Certara	$418.84 million	2.20	-$1.60 million	($0.01)	-600.00
Alpha Cognition	$10.22 million	14.59	-$20.67 million	($1.16)	-5.91

Certara has higher revenue and earnings than Alpha Cognition. Certara is trading at a lower price-to-earnings ratio than Alpha Cognition, indicating that it is currently the more affordable of the two stocks.

Summary

Certara beats Alpha Cognition on 9 of the 15 factors compared between the two stocks.

About Certara

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.

About Alpha Cognition

Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.